FAVIPIRAVIR

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Details

Stereochemistry	ACHIRAL
Molecular Formula	C5H4FN3O2
Molecular Weight	157.1026
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of FAVIPIRAVIR

Structure Search

SMILES

NC(=O)C1=NC(F)=CNC1=O

InChI

InChIKey=ZCGNOVWYSGBHAU-UHFFFAOYSA-N

InChI=1S/C5H4FN3O2/c6-2-1-8-5(11)3(9-2)4(7)10/h1H,(H2,7,10)(H,8,11)

HIDE SMILES / InChI

Molecular Formula	C5H4FN3O2
Molecular Weight	157.1026
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Approval Year

Substance Class	Chemical Created by `admin` on `Sat Dec 16 16:22:05 UTC 2023` Edited by `admin` on `Sat Dec 16 16:22:05 UTC 2023`
Record UNII	EW5GL2X7E0
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

FAVIPIRAVIR

Official Name

English

AVIGAN

Brand Name

English

6-Fluoro-3-hydroxypyrazine-2-carboxamide

Systematic Name

English

FAVIPIRAVIR [USAN]

Common Name

English

FAVIPIRAVIR [JAN]

Common Name

English

FAVIPIRAVIR [MI]

Common Name

English

Favipiravir [WHO-DD]

Common Name

English

2-PYRAZINECARBOXAMIDE, 6-FLUORO-3,4-DIHYDRO-3-OXO-

Systematic Name

English

T-705

Code

English

favipiravir [INN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C281

Created by admin on Sat Dec 16 16:22:06 UTC 2023 , Edited by admin on Sat Dec 16 16:22:06 UTC 2023

NCI_THESAURUS

C25995

Created by admin on Sat Dec 16 16:22:06 UTC 2023 , Edited by admin on Sat Dec 16 16:22:06 UTC 2023

Code System Code Type Description

WIKIPEDIA

Favipiravir

Created by admin on Sat Dec 16 16:22:06 UTC 2023 , Edited by admin on Sat Dec 16 16:22:06 UTC 2023

PRIMARY

CAS

259793-96-9

Created by admin on Sat Dec 16 16:22:06 UTC 2023 , Edited by admin on Sat Dec 16 16:22:06 UTC 2023

PRIMARY

MESH

C462182

Created by admin on Sat Dec 16 16:22:06 UTC 2023 , Edited by admin on Sat Dec 16 16:22:06 UTC 2023

PRIMARY

CHEBI

134722

Created by admin on Sat Dec 16 16:22:06 UTC 2023 , Edited by admin on Sat Dec 16 16:22:06 UTC 2023

PRIMARY

LACTMED

Favipiravir

Created by admin on Sat Dec 16 16:22:06 UTC 2023 , Edited by admin on Sat Dec 16 16:22:06 UTC 2023

PRIMARY

PUBCHEM

492405

Created by admin on Sat Dec 16 16:22:06 UTC 2023 , Edited by admin on Sat Dec 16 16:22:06 UTC 2023

PRIMARY

USAN

BC-05

Created by admin on Sat Dec 16 16:22:06 UTC 2023 , Edited by admin on Sat Dec 16 16:22:06 UTC 2023

PRIMARY

DRUG BANK

DB12466

Created by admin on Sat Dec 16 16:22:06 UTC 2023 , Edited by admin on Sat Dec 16 16:22:06 UTC 2023

PRIMARY

JAPANESE REVIEW

AVIGAN

Created by admin on Sat Dec 16 16:22:06 UTC 2023 , Edited by admin on Sat Dec 16 16:22:06 UTC 2023

PRIMARY

APPROVED MARCH 2014

SMS_ID

100000180049

Created by admin on Sat Dec 16 16:22:06 UTC 2023 , Edited by admin on Sat Dec 16 16:22:06 UTC 2023

PRIMARY

FDA UNII

EW5GL2X7E0

Created by admin on Sat Dec 16 16:22:06 UTC 2023 , Edited by admin on Sat Dec 16 16:22:06 UTC 2023

PRIMARY

INN

8916

Created by admin on Sat Dec 16 16:22:06 UTC 2023 , Edited by admin on Sat Dec 16 16:22:06 UTC 2023

PRIMARY

NCI_THESAURUS

C81605

Created by admin on Sat Dec 16 16:22:06 UTC 2023 , Edited by admin on Sat Dec 16 16:22:06 UTC 2023

PRIMARY

MERCK INDEX

m11863

Created by admin on Sat Dec 16 16:22:06 UTC 2023 , Edited by admin on Sat Dec 16 16:22:06 UTC 2023

PRIMARY

DRUG CENTRAL

4887

Created by admin on Sat Dec 16 16:22:06 UTC 2023 , Edited by admin on Sat Dec 16 16:22:06 UTC 2023

PRIMARY

ChEMBL

CHEMBL221722

Created by admin on Sat Dec 16 16:22:06 UTC 2023 , Edited by admin on Sat Dec 16 16:22:06 UTC 2023

PRIMARY

EPA CompTox

DTXSID60948878

Created by admin on Sat Dec 16 16:22:06 UTC 2023 , Edited by admin on Sat Dec 16 16:22:06 UTC 2023

PRIMARY

Related Record Type Details


					LR0F81F33L

ALDEHYDE OXIDASE

METABOLIC ENZYME -> SUBSTRATE

Interaction Type:

MAJOR


					ATA6VBL43H

XANTHINE DEHYDROGENASE/OXIDASE

METABOLIC ENZYME -> SUBSTRATE


					6D53G0FD0Z

PLASMA PROTEIN FRACTION (HUMAN)

BINDER->LIGAND

Interaction Type:

BINDING

Amount:


					0UC5UGK97L

5-DEUTEROFAVIPIRAVIR

ANALOGUE->PARENT


					B6L4N5Z4GH

SARS-COV2

TARGET ORGANISM->INHIBITOR

Comments:

DRUG APPROVED IN CHINA FOR COVID-19. Prodrug that InhibitS the RNA-dependent RNA polymerase after activation to triphosphate.

Amount:


					H9E46H7JYJ

RNA-DEPENDENT RNA POLYMERASE COMPLEX (COVID 2019 VIRUS)

TARGET -> INHIBITOR

Amount:

Related Record Type Details


					TX0QD8NI6C

5-HYDROXY-FAVIPIRAVIR

METABOLITE INACTIVE -> PARENT

Qualification:

URINE


					F0JG9C0OQD

FAVIPIRAVIR RIBOSIDE TRIPHOSPHATE

METABOLITE ACTIVE -> PRODRUG


					9CW9PD88PX

FAVIPIRAVIR-RIBOSE-5'-PHOSPHATE

METABOLITE -> PARENT

Related Record Type Details


					EW5GL2X7E0

ACTIVE MOIETY

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
Tmax	PHARMACOKINETIC				IN HEALTHY JAPANESE VOLUNTEERS ORAL ADMINISTRATION

Biological Half-life	PHARMACOKINETIC				ORAL ADMINISTRATION IN HEALTHY JAPANESE VOLUNTEERS